<DOC>
	<DOCNO>NCT01614938</DOCNO>
	<brief_summary>The purpose study compare efficacy toxicity docetaxel-cisplatin neoadjuvant chemotherapy follow concurrent radiotherapy cetuximab weekly cisplatin locally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Induction Chemotherapy Followed Concurrent Radiation With Cetuximab Cisplatin Locally Advanced Nasopharyngeal Cancer</brief_title>
	<detailed_description>Although concurrent chemoradiation standard treatment modality locally advanced nasopharyngeal carcinoma ( NPC ) , high incidence distant metastasis severe treatment related toxicity become obstacle overcome . A phase Ⅱ study conduct Hui et al . show neoadjuvant docetaxel-cisplatin ( TP ) chemotherapy follow concurrent chemoradiotherapy superior standard concomitant chemoradiation term 3-year OS without significantly exacerbate acute toxicity . Moreover , Bonner et al . demonstrate RT concurrent Cetuximab significantly improve 5-year OS increase treatment induced toxicity compare RT alone . Therefore , initiate study compare efficacy toxicity two regimen , neoadjuvant chemotherapy follow concurrent radiotherapy cetuximab weekly cisplatin locally advance NPC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Histopathologically proven nasopharyngeal carcinoma ( WHO type 2 3 ) 2 . Stage ⅢⅣB disease ( AJCC/UICC 2009 ) 3 . ECOG performance status 01 4 . Life expectancy 6 month 5 . Signed write informed consent 6 . Adequate organ function include follow : Absolute neutrophil count ( ANC ) &gt; = 1.5 * 109/l Platelets count &gt; = 100 * 109/l Hemoglobin &gt; = 10 g/dl AST ALT &lt; = 2.5 time institutional upper limit normal ( ULN ) Total bilirubin &lt; = 1.5 time institutional ULN Creatinine clearance &gt; = 50 ml/min Serum creatine &lt; = 1 time ULN 1 . Evidence distant metastasis 2 . Prior chemotherapy anticancer biologic therapy type cancer , prior radiotherapy head neck region 3 . Other previous concomitant cancer , except situ cervical cancer cutaneous basal cell carcinoma 4 . Pregnant breastfeeding female , female male childbearing potential take adequate contraceptive measure 5 . Presence uncontrolled concomitant illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Weekly cisplatin chemotherapy</keyword>
	<keyword>Intensity-modulated radiotherapy</keyword>
</DOC>